46 results on '"Riemekasten, G"'
Search Results
2. CLINICAL PHENOTYPE IN SCLERODERMA PATIENTS WITH ANTI-TOPOISOMERASE I POSITIVITY AND LIMITED CUTANEOUS FORM: DATA FROM THE EUSTAR DATABASE
3. LONG-TERM OUTCOME OF SSC ASSOCIATED ILD: IMPROVED SURVIVAL IN PPI TREATED PATIENTS
4. DOES ANTI-ACID TREATMENT INFLUENCE DISEASE PROGRESSION IN SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE (SSC-ILD)? DATA FROM THE GERMAN SSC-NETWORK
5. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
6. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis. a 10-year longitudinal study from the EUSTAR database
7. SSC IN OLDER AGE: FREQUENT AND WITH A DIFFERENT PHENOTYPE. DATA OF THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS
8. DYNAMIC OPTICAL COHERENCE TOMOGRAPHY MIGHT BE A VALUABLE TOOL TO ASSESS THERAPEUTIC EFFICACY OF VASOACTIVE THERAPY IN SYSTEMIC SCLEROSIS.
9. BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN A PHASE 2 STUDY TO EVALUATE EFFICACY, SAFETY, AND TOLERABILITY OF MT-7117 IN SUBJECTS WITH DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS.
10. SYNERGISTIC EFFECT OF AT1R-AUTOANTIBODIES AND EXTRACELLULAR VESICLES IN SSC PATHOGENESIS.
11. RITUXIMAB VS. COMBINATION OF RITUXIMAB AND CYCLOPHOSPHAMIDE INDUCTION THERAPY FOR ANCA-ASSOCIATED VASCULITIS: A RETROSPECTIVE STUDY.
12. AUTOANTIBODIES DIRECTED TO G-PROTEIN COUPLED RECEPTORS CORRELATE WITH DISEASE ACTIVITY SCORES IN PATIENTS WITH PSORIATIC ARTHRITIS.
13. AUTOANTIBODIES AGAINST FIBROBLAST GROWTH FACTOR (FGF-2), PLACENTAL GROWTH FACTOR (PLGF) AND BETA-ADRENERGIC RECEPTOR 1 (ADRB1) IN AN ALTERED NETWORK OF AUTOANTIBODIES IN SYSTEMIC SCLEROSIS.
14. COMPARISON OF FOUR RISK STRATIFICATION MODELS FOR PREDICTION OF MORTALITY IN SSc-PAH IN THE EUSTAR COHORT.
15. DIFFUSING CAPACITY AND CLINICAL CHARACTERISTICS OF PATIENTS WITH SYSTEMIC SCLEROSIS - DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS
16. A MIF PROMOTER POLYMORPHISM IS ASSOCIATED WITH THE SUSCEPTIBILITY TO PULMONARY ARTERIAL HYPERTENSION IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS PATIENTS
17. EVALUATION OF FREQUENCY AND TYPE OF PHYSICAL THERAPY IN MORE THAN 3400 PATIENTS WITH SYSTEMIC SCLEROSIS
18. TRANS-ETHNIC META-ANALYSIS OF GENOME-WIDE ASSOCIATION STUDIES IDENTIFIES GSDMA AND PRDM1 AS SUSCEPTIBILITY GENES TO SYSTEMIC SCLEROSIS
19. DISEASE PROGRESSION IN 282 PATIENTS WITH UNDIFFERENTIATED SSC - DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLERODERMA
20. ANALYSIS OF REAL LIFE VASOACTIVE THERAPY IN OVER 3000 PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) REVEALS CONSIDERABLE UNDERTREATMENT AND SIGNIFICANT CHANGES OF TREATMENT PRACTICE SINCE 2004
21. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres
22. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort.
23. EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research
24. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population
25. TGF[beta] receptor gene variants in systemic sclerosis-related pulmonary arterial hypertension: results from a multicentre EUSTAR study of European Caucasian patients.
26. NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis.
27. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis.
28. Association of the TNFAIP3 rs5029939 variant with systemic sclerosis in the European Caucasian population.
29. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians.
30. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis.
31. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases.
32. The binding of lupus-derived autoantibodies to the C-terminal peptide (83-119) of the major SmD1 autoantigen can be mediated by double-stranded DNA and nucleosomes.
33. T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus.
34. T cell reactivity against the SmD183-119 C terminal peptide in patients with systemic lupus erythematosus.
35. A large multicentre analysis of CTGF -945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype.
36. A large multicentre analysis of CTGF −945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype.
37. Targeting activated T cells: successful use of anti-CD25 monoclonal antibody basiliximab in a patient with systemic sclerosis.
38. Responders to cyclophosphamide: results of a single-centre analysis among systemic sclerosis patients.
39. The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study.
40. Systemic sclerosis – agonistic auto-antibodies directed against the angiotensin receptor type 1 and the endothelin receptor type A and their effects on immune cells.
41. CD4 T cells producing IL-10 have a beneficial effect in murine lupus.
42. Variants of PBEF predispose to systemic sclerosis and pulmonary arterial hypertension development.
43. Polymorphisms in the interleukin 4, interleukin 13 and corresponding receptor genes are not associated with systemic sclerosis and do not influence gene expression.
44. Interleukin10-producing CD4 T cells ameliorate murine lupus in NZB/W F1 mice.
45. Systemic sclerosis as prototypic disease with high levels of functional antibodies against angiotensin II type-1 and endothelin-1 type A receptor strongly predicting prognosis.
46. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.